SM
TTPH

Sabby Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Sabby Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-667,000
Closed -$854K – 141
2020
Q1 		$854K Buy
+667,000
New +$1.36M 0.35% 27
2015
Q4 		– Sell
-4,059
Closed -$606K – 397
2015
Q3 		$606K Buy
+4,059
New +$2.98M 0.03% 279

Other funds holding TTPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sabby Management's TTPH Position: Q2 2020 in Review

Sabby Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2020, closing a stake of 667,000 shares — an estimated $854K sold.

Sabby Management first reported a position in TTPH in Q3 2015 and held it in 2 quarters. The position peaked at $854K in Q1 2020. 26 funds tracked by Wall St. Rank hold TTPH as of Q2 2020.

  • Sabby Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Sabby Management sold 667,000 Tetraphase Pharmaceuticals, Inc. shares in Q2 2020, an estimated $854K.
  • Sabby Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Sabby Management's Tetraphase Pharmaceuticals, Inc. position peaked at $854K in Q1 2020.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.